Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Mise à jour : Il y a 4 ans
Référence : NCT00821600

Femme et Homme

Extrait

The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the gluteal muscle.


Critère d'inclusion

  • Psychotic disorders ,Schizophrenia

Liens